Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients
Status:
Completed
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
Background:
The first case of Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
were diagnosed in Wuhan, China in 2019. In the first half of 2020 this disease has already
converted into a global pandemic. Objectives: To assess the efficacy of Ivermectin in mild
cases of COVID-19 patients on the basis of predefined assessment criteria. Study Settings:
Fatima Memorial Hospital, Lahore Study Design: Open label randomized control trial. Duration
of Study: From 1st May, 2020 to 30th June, 2020.Patients & Methods: Sample size and
technique: Sample size was 50 patients; 25 patients were kept in control group and 25
patients were kept in experimental group